Fusion Antibodies (FAB) Competitors

Fusion Antibodies (LON:FAB) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation.

Is FAB or OKYO more profitable?

OKYO Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -137.11% beat OKYO Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fusion Antibodies	-195.95%	-137.11%	-63.78%
OKYO Pharma	N/A	-397.13%	-154.72%

Which has better valuation and earnings, FAB or OKYO?

Fusion Antibodies has higher revenue and earnings than OKYO Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fusion Antibodies	£2.09M	3.00	-£4.10M	-£4.45	-1.50
OKYO Pharma	N/A	N/A	-£6.70M	-£0.01	N/A

Does the MarketBeat Community prefer FAB or OKYO?

Fusion Antibodies received 47 more outperform votes than OKYO Pharma when rated by MarketBeat users. Likewise, 68.35% of users gave Fusion Antibodies an outperform vote while only 63.64% of users gave OKYO Pharma an outperform vote.

Company	Underperform	Outperform
Fusion Antibodies	Outperform Votes 54 68.35%	Underperform Votes 25 31.65%
OKYO Pharma	Outperform Votes 7 63.64%	Underperform Votes 4 36.36%

Does the media favor FAB or OKYO?

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.

Company	Overall Sentiment
Fusion Antibodies	Neutral
OKYO Pharma	Neutral

Which has more volatility and risk, FAB or OKYO?

Fusion Antibodies has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.

Do insiders and institutionals believe in FAB or OKYO?

21.0% of Fusion Antibodies shares are owned by institutional investors. 11.4% of Fusion Antibodies shares are owned by insiders. Comparatively, 31.9% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Fusion Antibodies beats OKYO Pharma on 9 of the 12 factors compared between the two stocks.